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Nondigital lower extremity ulcers are a diﬃcult to treat complication of scleroderma, and a significant cause of morbidity.
The purpose of this study was to evaluate the prevalence of nondigital lower extremity ulcers in scleroderma and describe the
associations with autoantibodies and genetic prothrombotic states. A cohort of 249 consecutive scleroderma patients seen in the
Georgetown University Hosptial Division of Rheumatology was evaluated, 10 of whom had active ulcers, giving a prevalence of
4.0%. Patients with diﬀuse scleroderma had shorter disease duration at the time of ulcer development (mean 4.05 years ± 0.05)
compared to those with limited disease (mean 22.83 years ± 5.612, P value .0078). Ulcers were bilateral in 70%. In the 10 patients
with ulcers, antiphospholipid antibodies were positive in 50%, and genetic prothrombotic screen was positive in 70% which is
higher than expected based on prevalence reports from the general scleroderma population. Of patients with biopsy specimens
available (n = 5), fibrin occlusive vasculopathy was seen in 100%, and all of these patients had either positive antiphospholipid
antibody screen, or positive genetic prothrombotic profile. We recommend screening scleroderma patients with lower extremity
ulcers for the presence of anti-phospholipid antibodies and genetic prothrombotic states.
1. Introduction
Non-digital lower extremity ulcers are a diﬃcult to treat
complication of scleroderma seen both in limited and diﬀuse
scleroderma and also in scleroderma sine scleroderma. They
contribute to the pain and disability of advanced disease.
The etiology of these ulcers is unknown, but they may reflect
chronic vasculopathy.
The prevalence of nonhealing lower extremity ulcers in
scleroderma has not specifically been studied. Older data
from the Pittsburgh Scleroderma Databank identified seven
out of 1030 patients requiring amputation for refractory leg
ulcers, giving an incidence of wounds requiring amputation
of 0.67% [1]. However, this is likely to be an underestimate of
total prevalence of leg ulcers, sincemost scleroderma patients
with leg ulcers do not require amputation. More recently,
Alivernini et al. evaluated 130 scleroderma patients over a 20-
month period. They identified 26.15%with digital ulcers and
3.8% with “other” ulcers [2], and the latter may be a more
accurate estimate of the true prevalence of non-digital lower
extremity ulcers.
The impact of leg ulceration on health care costs and
quality of life has not been studied in the scleroderma
population. Extrapolating from other chronic diseases such
as diabetes, it is known that leg ulcers result in significant
morbidity and mortality, leading to recurrent hospitaliza-
tions, repeated surgeries, and significant costs to the health
care system. A retrospective study of patients with diabetes
and leg ulcers found that, in the first two years after diagnosis,
the costs attributable to the ulcer were $27,987 [3].
Scleroderma is associated with delayed wound healing
[2], and as with other chronic leg ulcers, the etiology of
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delayed healing is likely to be multifactorial. Some have
postulated a role for larger vessel venous and arterial disease
[4], but many scleroderma ulcers remain refractory even
after restoration of good blood flow and venous drainage.
Biopsy data from scleroderma wounds demonstrates fib-
rin plugging of the small vessels and persisting macrophage
and fibroblast activation, suggesting that these wounds may
be arrested in a chronic inflammatory phase. A similar fibrin
occlusive vasculopathy is seen in biopsies of leg ulcers due
to livedoid vasculopathy. Livedoid vasculopathy is associated
with impaired fibrinolysis from a variety of genetic and
acquired causes [5–7] and heparin an anticoagulant with
profibrinolytic actions has been eﬀective in some cases [8–
10]. We postulate that dysregulation of the complement and
coagulation cascades with inadequate fibrinolysis and angio-
genesis may contribute to delayed healing in scleroderma-
associated lower extremity ulcers.
In autoimmune diseases, antiphospholipid antibodies are
recognized as activators of both coagulation and comple-
ment cascades [11, 12]. Preliminary data in our connec-
tive tissue disease population has suggested an association
between autoimmune ulcers and both antiphospholipid
antibodies and genetic prothrombotic states [13].
The primary aim of the current study was to evaluate
the prevalence of lower extremity ulcers in our scleroderma
population. The secondary aim of this study was to evaluate
the presence of antiphospholipid antibodies and genetic
prothrombotic states in patients with scleroderma-associated
leg ulcers. The outcomes of empiric therapy in the small
number of patients evaluated in this study are reported.
2. Methods
This study was approved by the Biomedical Institutional
Review Board at Georgetown University Medical Center as
part of the Connective Tissue Disease Leg Ulcer Etiology
(CLUE) study.
2.1. Patient Selection for Prevalence Evaluation. All scle-
roderma patients followed in the Georgetown University
Hospital Division of Rheumatology and Wound Healing
Center between August 2007 and August 2009 were evaluated
for the presence of non-digital lower extremity ulcers. Active
leg ulceration was defined as presence of non-digital lower
extremity wounds that have been refractory to standard
wound care for more than 3 months.
2.2. Laboratory Studies. Patients with active ulcers under-
went autoimmune testing including antinuclear antibody
by immunofluorescence (ANA), anti-Scl70 antibody, anti-
centromere antibody, antidouble stranded DNA antibody
(dsDNA), anti-Sm antibody (Sm), anti-U1-RNP antibody
(RNP), anti-Ro antibody (SSA), anti-La antibody (SSB),
rheumatoid factor, and anticyclic citrullinated peptide. Pro-
thrombotic evaluation was also completed in all patients
including prothrombin gene mutation, plasminogen acti-
vator inhibitor-I mutation (PAI-I), methyltetrahydrofolate
reductase mutation (MTHFR C677T), Factor V Leiden
(FVL), protein S functional activity, protein C functional
activity, antithrombin III functional activity, anticardiolipin
IgG, IgA, and IgM titers, anti-β2-glycoprotein I IgG, IgA and
IgM titers, and lupus anticoagulant.
2.3. Venous and Arterial Testing. All patients had evaluation
of ankle-brachial pressure index and venous Doppler ultra-
sound studies to identify any concomitant venous or arterial
disease. If present, patients were referred to vascular surgery
for therapy.
2.4. Biopsy. Surgical debridement of wounds was performed
if clinically indicated, as determined by the wound healing
attending physician (CEA). If debridement was performed,
biopsies, including a small piece of normal skin at the edge
of the lesion, were taken. This is standard procedure in
our center when evaluating for the presence or absence
of vasculitis and is thought to give the highest yield of
detecting small vessel vasculitis in vessels away from the base
of the ulcer. All specimens were evaluated by an attending
pathologist and the primary investigator (VKS), both of
whom are experienced at reviewing skin biopsy specimens
for the presence of vasculitis. The specimens were graded as
to the presence or absence of fibrin plugging, leukocytoclastic
vasculitis, or vessel necrosis.
2.5. Evaluation for Infection. It is well known that many
chronic wounds become colonized with bacteria, but not
all colonized wounds are infected. Following standard pro-
cedure in the Center for Wound healing, all patients were
evaluated at each visit for symptoms or signs of acute
infection, based on presence of purulence, odor, ascending
erythema, fever, or systemic symptoms. If infection was
present, the wound was debrided, and antibiotics were
initiated and tailored according to the results of deep cultures
taken in the operating room [14].
2.6. Local Therapy. Patients were treated with aggressive local
wound therapy as determined by standardized protocols
used by the Center for Wound Healing [14]. Patients with
associated macrovascular disease were referred for surgical
intervention. Dressings were selected to promote wound
healing based on accepted criteria of maintaining high
humidity at the wound-dressing interface, removing excess
exudate, promoting gaseous exchange, providing thermal
insulation, being impermeable to bacteria and other con-
taminants, and being removable without causing trauma to
the wound bed. At each follow-up visit ulcer planimetry was
used to assess interval change in ulcer size. Reduction in size
at a rate of 10% per week was consistent with healing.
2.7. Systemic Therapy. Based on case reports in the literature,
open label low-dose, low-molecular-weight heparin (Enoxa-
parin, 40mg subcutaneously once daily, Sanofi-Aventis) was
used in four patients [9, 10], and darbopoetin alfa (Aranesp,
0.45mcg/Kg subcutaneously once weekly, Amgen Inc.) was
used in one patient [15]. The outcomes of these interventions
are reported.
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2.8. Pain and Quality of Life Assessment. At the initial
visit and upon healing of the wound, patients were asked
to complete visual analogue pain score and two quality
of life assessments, the Short Form 36 (SF36) which has
been validated in many populations including those with
scleroderma [16], and diabetic leg ulcers [17] and the Cardiﬀ
Wound Impact Schedule (CWIS) which was specifically
developed for assessing the impact of leg ulcers on quality-
of-life and which has been validated in a population of
patients with refractory leg ulcers [18]. Both the SF-36
and the Cardiﬀ Wound Impact Schedule are validated
quality-of-life instruments in which the patients’ answers to
specific questions are scored. The scores are computed using
validated formulae to calculate a total score from 0 (worst
quality of life) to 100 (best quality of life).
2.9. Statistical Analysis. Demographic data was analyzed
using descriptive statistics. Interval change in wound percent
surface area was calculated at each visit, and wounds were
stratified as healed, healing (defined as a reduction of
surface area >10% per week), or open (reduction in surface
area <10% per week). Quality-of-life and pain scores were
analyzed according to wound status (open or healed) at
the time the data was recorded, and paired t-test was
used to analyze these results. Due to the small number of
patients being studied and the uncontrolled nature of the
interventions in these patients, no statistical analysis was
performed on the outcome data.
3. Results
3.1. Prevalence of Leg Ulcers in Scleroderma. Between August
2007 and August 2009, 10 of 249 scleroderma patients
had active leg ulcers. The prevalence of leg ulcers in our
scleroderma population was therefore 4.0%.
3.2. Demographic Features. Of the 10 patients with sclero-
derma associated leg ulcers, 2 had diﬀuse scleroderma; 6 had
limited scleroderma, and 2 had scleroderma sine scleroderma
(Table 1). Consistent with our scleroderma population, 70%
were female, and 90% were Caucasian. The age at first ulcer
was normally distributed with a mean age of 59.90 years
(range, 42 to 76 years, median 59.50 years).
3.3. Disease Duration. The duration of scleroderma at the
time of first ulcer development was also normally distributed
with a mean age of 18.14 years (range from 4 to 46 years,
median 18.5 years). The 2 patients with diﬀuse scleroderma
had shorter disease duration prior to ulcer development
(mean 4.05 years ± 0.05) compared to those with limited
scleroderma (mean 22.83 years ± 5.612, P-value .0078).
3.4. Ulcer Distribution. Ulcers were bilateral in 7 of the
10 patients (70%). Notably, all three of the patients with
unilateral lesions had underlying large vessel disease (two
with arterial disease and one with venous insuﬃciency based
on Doppler ultrasound measurements). Of the patients with
bilateral ulcers, all had lesions in the perimalleolar or anterior
ankle region, and two patients additionally had more distal
lesions on the feet.
Figure 1: Biopsy of patient 7 showing fibrin occlusive vasculopathy
(arrow).
3.5. Biopsy Findings. Biopsy specimens were available for
review in 5 of the 10 patients (Table 1). All five biopsies
showed fibrin plugging and vasculopathy changes as seen
in Figure 1. None of the biopsy specimens had evidence of
vasculitis.
3.6. Antibody Profile. The autoantibody profile is listed in
Table 1. Anticentromere antibody was positive in four of
the six patients with clinically limited disease. One patient
had positive Scl70 antibody, and the other patient was a
man with clinically limited scleroderma and positive SSA
antibody. Two patients had clinically diﬀuse scleroderma.
One had antitopoisomerase antibody (Scl-70), and another
was positive for RNA polymerase III (pol 3). All patients had
normal complement levels.
3.7. Antiphospholipid Profile. The results of the antiphospho-
lipid profiles are shown in Table 1. All 10 patients had at
least one antiphospholipid profile, and 9 patients had two
phospholipid profiles 12 weeks apart, as it is recommended
to confirm the presence of antiphospholipid antibodies [19].
Of the 10 patients, 5 had persistently positive antiphos-
pholipid antibodies, giving a prevalence of antiphospholipid
antibodies in this group of scleroderma patients with leg
ulcers of 50%. Although phospholipid antibody data was not
available on the cohort of scleroderma patients without leg
ulcers in this study, these rates are higher than reported in
the general scleroderma population. Of the 5 patients with
persistently positive antibodies, 4 additionally had a history
of pregnancy morbidity or vascular thrombosis although
they were not on chronic anticoagulation.
3.8. Procoagulant Profile. The genetic procoagulant profile
is also listed in Table 1. Homozygous or heterozygous
mutation for methyltetrahydrofolate reductase (MTHFR)
C677T mutation was seen in 7 of the 10 patients (70%).
Plasminogen activator inhibitor gene (PAI-1) mutation was
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heterozygous positive in 3 patients and homozygous in 1
patient (40%). Factor V leiden and prothrombin gene muta-
tions were not identified in any patient studied. All patients
had normal protein C, S, and anti-thrombin III activity.
3.9. Pain and Quality of Life. Pain and quality-of-life data
was available in 7 patients enrolled in the CLUE study.
Pain score was significantly lower in patients with healed
wounds (0.6 ± 0.6) compared to those with open lesions
(5.025 ± 1.007, P .0351), clearly demonstrating that wound
healing correlates with a dramatic improvement in pain.
The CWIS well-being score was significantly better in the
patients with healed wounds (58.84 ± 5.465) compared to
those with open wounds (37.93 ± 3.757, P.0334). The CWIS
physical score was also higher in the patients with healed
wounds (86.97± 1.57) compared to those with open wounds
(59.62 ± 6.295, P .0358). However, there was no diﬀerence
in social functioning with wound healing. Analysis of the SF-
36 data in this small population did not identify significant
diﬀerences between the healed and unhealed wounds in any
of the SF-36 domains.
3.10. Response to Therapy. Due to the association of ulcers
with antiphospholipid antibodies and the successful out-
comes seen in patients with livedoid vasculopathy, low-
dose, low-molecular weight heparin (Enoxaparin, 40mg
subcutaneously once daily, Sanofi-Aventis) was used in 5
patients. Rapid and complete healing was seen in 2 of
the patients (patient 1 and patient 6); both of whom had
positive antiphospholipid antibodies. Patient 7 just recently
commenced therapy with low-dose enoxaparin and to date
has demonstrated 50% reduction in ulcer surface area in
3 months. Patient 4 developed bleeding with low dose
enoxaparin and had to discontinue the medication. She
was subsequently treated with darbopoetin alfa (Aranesp,
0.45mcg/Kg subcutaneously once weekly, Amgen, Inc.) for
anemia, and this resulted in complete healing of the ulcer.
Patient 3 had negative antiphospholipid antibodies but
homozygous mutation for MTHFR C677T and heterozygous
mutation for PAI-1. To date, she has been refractory to low-
molecular-weight heparin even at doses of 1mg/kg twice
daily. She remains unhealed after 350 months of follow-
up. Pentoxifylline, a xanthine derivative with anti-TNF and
fibrinolytic actions, was used in one patient (patient 5) with
healing of the ulcers.
3.11. Prognosis of Leg Ulcers in Scleroderma. Of the 10
scleroderma patients with leg ulcers prospectively followed
in this study, all had open lesions for ≥3 months. Complete
healing has been seen in 6 patients (2 with LMWH, 1 with
darbopoetin alfa, 1 with pentoxifylline, 1 with nifedipine,
and 1 with arterioplasty), and one patient is responding
to LMWH though not completely healed. Ulcers remain
refractory to healing in three patients.
4. Discussion
The prevalence of non-healing lower extremity ulcers in
our scleroderma population was 4%. In this study all
scleroderma patients presenting to the Rheumatology Clinic
were evaluated for scleroderma-associated leg ulcers. While
there may be a perceived bias because of our special interest
in scleroderma-associated lower extremity ulcers, only two
patients were identified who were not previously known
to have scleroderma both of whom had scleroderma sine
scleroderma. Based on this finding, we think that the
prevalence reported is likely a true estimate of prevalence
of non-healing lower extremity wounds in scleroderma.
Furthermore, this highlights the importance of evaluating
patients with non-healing wounds for scleroderma even in
the absence of overt skin changes. No other studies have
specifically evaluated a cohort of scleroderma patients for
non-digital ulcer prevalence, but our data are in line with that
reported by Alivernini et al. [2]. The cumulative incidence
of diabetic leg ulcers over a 5-year period has been reported
at 5.8% [3], suggesting that the frequency of leg ulcers in
scleroderma approaches that seen in diabetes.
Biopsy studies were available in 50% of patients in
this study. We did not identify vasculitis in any of the
biopsied wounds. While any biopsy always carries a risk
of sampling error, we believe that biopsies which include
the subcutaneous tissue and a perimeter of normal skin at
the edge of the wound are usually suﬃcient to confirm the
presence or absence of vasculitis [14].
Our study design had significant limitations since we
do not have funding or IRB approval to screen our entire
scleroderma population for prevalence of antiphospholipid
antibodies and genetic prothrombotic states. This limits our
ability to draw firm conclusions regarding the associations
with lower extremity ulcers.
Although our study was limited due to the sample
size and study design, we were able to demonstrate that
scleroderma associated ulcers are refractory to usual wound
care therapies. Additionally, while the quality of life ques-
tionnaires administered in this study work best in large
population studies, our data do suggest that presence of open
wounds in scleroderma adversely impact quality-of-life over
and above the underlying scleroderma.
The prevalence of antiphospholipid antibodies in our
cohort of patients with ulcers was higher than that reported
in the general scleroderma population (50% compared to
between 3.3 and 12%) [20–22]. Several other studies suggest
an association between antiphospholipid antibodies and
lower extremity ulcers in scleroderma. Lupus anticoagulant
has been identified as a strong predictor of ulcer pres-
ence in scleroderma patients (OR 7.2) [2]. Furthermore,
cutaneous ulcers are more frequent in scleroderma patients
with antiphospholipid antibodies than those without (63%
compared to 39%) [22]. Finally, a study reporting a series of
eight patients with concomitant scleroderma and antiphos-
pholipid syndrome identified three patients (37.5%) with
associated leg ulcers [23], a much higher prevalence than we
found in our more general scleroderma population.
MTHFR C677T heterozygous or homozygous mutation
was also higher than expected in our cohort of scleroderma
patients with leg ulcers. We found a prevalence of 60% for
the heterozygous mutation and 10% for the homozygous
mutation whereas in the general scleroderma population
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49% expressed wild type (no mutation), 36% were heterozy-
gous, and 15% were homozygous for the mutation [24]. Our
population of patients with scleroderma associated leg ulcers
had a prevalence of the plasminogen activator inhibitor gene
(PAI-1) mutation of 40%. This is on a par with frequencies
of this gene mutation in other populations, with the 4G allele
being reported at a frequency of 62% in healthy pregnant
women [25].
The outcome of the small number of patients treated
with low-molecular-weight heparin therapy is promising.
When tolerated, we found a 50% complete healing rate.
Furthermore, response did not require full therapeutic
doses of heparin, suggesting that, heparin may be acting
via antiphospholipid-dependent pathways, such as com-
plement activation and fibrinolysis, rather than purely
through its anticoagulant eﬀect as has been reported for
antiphospholipid-associated pregnancy losses [12]. Only one
patient in our study was treated with darbopoetin alfa but
this resulted in complete healing of her ulcer. A similar
response has been reported in one other case report [15].
The erythropoietin analogues are increasingly recognized as
stimulators of angiogenesis pathways, and therefore these
pathways may merit further investigation in scleroderma
[26].
5. Conclusions
Lower extremity ulcers are seen in 4% of scleroderma
patients and cause pain and morbidity over and above
that of the scleroderma. In this small study we identi-
fied higher than expected frequency of antiphospholipid
antibodies and MTHFR mutation. We recommend that
scleroderma patients who develop leg ulcers should undergo
prothrombotic evaluation. Clearly this small uncontrolled
study is insuﬃcient to draw clear conclusions as to etiology
of delayed wound healing in scleroderma. However, lower
extremity ulcers represent a challenging clinical problem
in scleroderma and further studies into their pathogenesis
and potential therapies may yield new insights into the
vasculopathy of scleroderma at a cellular andmolecular level.
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